Standard InChI: InChI=1S/C22H30N6O3S/c1-27(2)13-6-16-31-19-9-7-18(8-10-19)20-17-21(26-22(25-20)32(3,29)30)23-11-4-14-28-15-5-12-24-28/h5,7-10,12,15,17H,4,6,11,13-14,16H2,1-3H3,(H,23,25,26)
Standard InChI Key: MSIJJXOWLFOYIN-UHFFFAOYSA-N
Associated Targets(Human)
Cat eye syndrome critical region protein 2 340 Activities
1.Lucas SCC, Atkinson SJ, Bamborough P, Barnett H, Chung CW, Gordon L, Mitchell DJ, Phillipou A, Prinjha RK, Sheppard RJ, Tomkinson NCO, Watson RJ, Demont EH.. (2020) Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode., 63 (10):[PMID:32321240][10.1021/acs.jmedchem.0c00021]
2.Mélin L, Calosing C, Kharenko OA, Hansen HC, Gagnon A.. (2021) Synthesis of NVS-BPTF-1 and evaluation of its biological activity., 47 [PMID:34146702][10.1016/j.bmcl.2021.128208]
3.Zahid H, Buchholz CR, Singh M, Ciccone MF, Chan A, Nithianantham S, Shi K, Aihara H, Fischer M, Schönbrunn E, Dos Santos CO, Landry JW, Pomerantz WCK.. (2021) New Design Rules for Developing Potent Cell-Active Inhibitors of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition., 64 (18.0):[PMID:34515477][10.1021/acs.jmedchem.1c01294]
4.Lu T, Lu H, Duan Z, Wang J, Han J, Xiao S, Chen H, Jiang H, Chen Y, Yang F, Li Q, Chen D, Lin J, Li B, Jiang H, Chen K, Lu W, Lin H, Luo C.. (2021) Discovery of High-Affinity Inhibitors of the BPTF Bromodomain., 64 (16.0):[PMID:34375106][10.1021/acs.jmedchem.1c00721]
